查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607225

Guillain-Barré二氏症候群市場：按類型、治療方法和最終用戶分類 - 全球預測 2025-2030

Guillain-Barre Syndrome Market by Type, Treatment, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年Guillain-Barré二氏症候群市場價值為6.3443億美元，預計到2024年將達到6.6539億美元，複合年成長率為2.10%，預計到2030年將達到7.3424億美元。

Guillain-Barré二氏症候群(GBS) 是一種急性免疫介導的疾病，會影響周邊神經系統，導致快速進行性虛弱和潛在的癱瘓。作為 360iResearch 的市場研究分析師，了解 GBS 相關醫療介入和治療的範圍、需求和使用至關重要。 GBS主要需求於神經科科診所、醫院和復健中心，因為它需要快速的醫療診斷、免疫治療和復健服務。隨著全球盛行率的上升、認知的提高和診斷技術的增強，GBS 市場有望成長。關鍵的成長要素包括支持性護理的進步以及靜脈注射免疫球蛋白和血漿置換等治療解決方案的進步。製藥公司增加醫療保健投資和新療法的研究經費也將推動市場向前發展。此外，更容易患自體免疫疾病的人口老化正在推動需求。然而，該市場面臨局限性，包括治療成本高、準確診斷GBS的複雜性以及由於症狀與其他神經系統疾病的相似性而存在誤診的風險。監管挑戰和新療法嚴格的核准流程構成了障礙，使市場擴張更加複雜。儘管存在這些挑戰，但開發旨在超越當前治療方法的創新療法的機會仍然存在。個人化醫療、再生療法和基因組解決方案等新興領域為差異化和成長提供了令人興奮的前景。此外，利用人工智慧和機器學習進行準確的早期診斷有可能徹底改變患者的治療結果並提供長期的商機。最後，學術機構和醫療保健公司之間合作進行臨床試驗和研究可以促進創新。因此，對於想要在不斷發展的 GBS 市場中建立據點的公司來說，強調強大的研發、策略夥伴關係和高效的醫療保健服務系統至關重要。

主要市場統計
基準年[2023] 63443萬美元
預計年份 [2024] 66539萬美元
預測年份 [2030] 7.3424億美元
複合年成長率（%） 2.10%

市場動態：針對快速發展的Guillain-Barré二氏症候群市場揭示的關鍵市場洞察

供需的動態交互作用正在改變Guillain-Barré二氏症候群市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • Guillain-Barré二氏症候群在全球的盛行率不斷擴大
    • 擴大靜脈注射免疫球蛋白注射治療Guillain-Barré二氏症候群的應用
    • 提高消費者的醫療保健意識和支出
  • 市場限制因素
    • 治療和藥物費用上漲
  • 市場機會
    • Guillain-Barré二氏症候群的治療進展
    • 罕見疾病政府優惠報銷政策
  • 市場挑戰
    • 疾病診治意識淡薄

波特的五力：駕馭Guillain-Barré二氏症候群市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解Guillain-Barré二氏症候群市場的外部影響

外部宏觀環境因素在塑造Guillain-Barré二氏症候群市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解Guillain-Barré二氏症候群市場的競爭狀況

對Guillain-Barré二氏症候群市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣Guillain-Barré二氏症候群市場供應商的績效評估

FPNV 定位矩陣是評估Guillain-Barré二氏症候群市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了Guillain-Barré二氏症候群市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對Guillain-Barré二氏症候群市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界範圍Guillain-Barré二氏症候群的盛行率增加
      • 靜脈注射免疫球蛋白擴大用於治療Guillain-Barré二氏症候群
      • 提高消費者的醫療保健意識和支出
    • 抑制因素
      • 治療和藥物費用上漲
    • 機會
      • Guillain-Barré二氏症候群的治療進展
      • 罕見疾病政府優惠報銷政策
    • 任務
      • 疾病診治意識淡薄
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章Guillain-Barré二氏症候群市場：依類型

  • 急性發炎去髓鞘化神經炎
  • 急性運動/感覺軸突神經病變
  • 急性運動軸突神經病變
  • 米勒-費雪綜合症

第7章Guillain-Barré二氏症候群治療市場

  • 水療
  • 藥物治療
  • 物理治療
  • 血漿置換

第8章Guillain-Barré二氏症候群市場：依最終用戶分類

  • 診斷中心
  • 醫院

第9章 美洲Guillain-Barré二氏症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區Guillain-Barré二氏症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東與非洲Guillain-Barré二氏症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Akari Therapeutics Plc
  • Annexon Inc.
  • Cellenkos Inc.
  • CSL Limited
  • CuraVac Europe SA
  • Electrical Geodesics Inc.
  • Grifols SA
  • Hansa Biopharma
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-450A0628D980

The Guillain-Barre Syndrome Market was valued at USD 634.43 million in 2023, expected to reach USD 665.39 million in 2024, and is projected to grow at a CAGR of 2.10%, to USD 734.24 million by 2030.

Guillain-Barre Syndrome (GBS) is an acute, immune-mediated disorder affecting the peripheral nervous system, leading to rapidly progressing weakness and potential paralysis. As a market research analyst at 360iResearch, it is vital to understand the scope, necessity, and applications of GBS-related medical interventions and treatments. GBS primarily requires rapid medical diagnosis, immunotherapy, and rehabilitation services, leading to growing demand in neurology clinics, hospitals, and rehabilitation centers. With an increasing incidence rate globally, attributed to rising awareness and enhanced diagnostic techniques, the GBS market is poised for growth. Key growth factors include advancements in therapeutic solutions, such as intravenous immunoglobulins and plasmapheresis, alongside advancements in supportive care. Increasing healthcare investment and research funding for novel therapies by pharmaceutical companies also propel the market forward, while the aging population, more prone to autoimmune disorders, drives demand. However, the market faces limitations, including high costs associated with treatment and the complexity of accurately diagnosing GBS, compounded by a threat of misdiagnosis due to symptom similarity with other neurological disorders. Regulatory challenges and stringent approval processes for new therapies present hurdles, further complicating market expansion. Despite these challenges, opportunities abound in the development of innovative therapeutics aimed at advancing beyond current treatment regimens. Emerging areas such as personalized medicine, regenerative therapy, and genomic solutions offer exciting prospects for differentiation and growth. Additionally, leveraging AI and machine learning for accurate early diagnosis could revolutionize patient outcomes, offering long-term business opportunities. Lastly, collaboration between academic institutions and healthcare companies to conduct clinical trials and research can drive innovation. Therefore, an emphasis on robust R&D, strategic partnerships, and efficient healthcare delivery systems will be crucial for companies aiming to establish a stronghold in the evolving GBS market.

KEY MARKET STATISTICS
Base Year [2023] USD 634.43 million
Estimated Year [2024] USD 665.39 million
Forecast Year [2030] USD 734.24 million
CAGR (%) 2.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Guillain-Barre Syndrome Market

The Guillain-Barre Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of Guillain-Barre syndrome worldwide
    • Growing adoption of intravenous immunoglobulins for treatment of Guillain-Barre syndrome
    • Rising consumer healthcare awareness and expenditures
  • Market Restraints
    • High costs of treatment and drugs
  • Market Opportunities
    • Advances in management of Guillain-Barre syndrome
    • Favorable governmental reimbursement policies for rare diseases
  • Market Challenges
    • Less awareness towards disease diagnosis and treatment

Porter's Five Forces: A Strategic Tool for Navigating the Guillain-Barre Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Guillain-Barre Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Guillain-Barre Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Guillain-Barre Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Guillain-Barre Syndrome Market

A detailed market share analysis in the Guillain-Barre Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Guillain-Barre Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Guillain-Barre Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Guillain-Barre Syndrome Market

A strategic analysis of the Guillain-Barre Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Guillain-Barre Syndrome Market, highlighting leading vendors and their innovative profiles. These include Akari Therapeutics Plc, Annexon Inc., Cellenkos Inc., CSL Limited, CuraVac Europe S.A., Electrical Geodesics Inc., Grifols S.A., Hansa Biopharma, Kedrion Biopharma Inc., Octapharma AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Guillain-Barre Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Acute Inflammatory Demyelinating Polyneuropathy, Acute Motor & Sensory Axonal Neuropathy, Acute Motor Axonal Neuropathy, and Miller Fisher Syndrome.
  • Based on Treatment, market is studied across Hydrotherapy, Medication, Physical Therapy, and Plasmapheresis.
  • Based on End-User, market is studied across Diagnostic Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of Guillain-Barre syndrome worldwide
      • 5.1.1.2. Growing adoption of intravenous immunoglobulins for treatment of Guillain-Barre syndrome
      • 5.1.1.3. Rising consumer healthcare awareness and expenditures
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of treatment and drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in management of Guillain-Barre syndrome
      • 5.1.3.2. Favorable governmental reimbursement policies for rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Less awareness towards disease diagnosis and treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Guillain-Barre Syndrome Market, by Type

  • 6.1. Introduction
  • 6.2. Acute Inflammatory Demyelinating Polyneuropathy
  • 6.3. Acute Motor & Sensory Axonal Neuropathy
  • 6.4. Acute Motor Axonal Neuropathy
  • 6.5. Miller Fisher Syndrome

7. Guillain-Barre Syndrome Market, by Treatment

  • 7.1. Introduction
  • 7.2. Hydrotherapy
  • 7.3. Medication
  • 7.4. Physical Therapy
  • 7.5. Plasmapheresis

8. Guillain-Barre Syndrome Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals

9. Americas Guillain-Barre Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Guillain-Barre Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Guillain-Barre Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akari Therapeutics Plc
  • 2. Annexon Inc.
  • 3. Cellenkos Inc.
  • 4. CSL Limited
  • 5. CuraVac Europe S.A.
  • 6. Electrical Geodesics Inc.
  • 7. Grifols S.A.
  • 8. Hansa Biopharma
  • 9. Kedrion Biopharma Inc.
  • 10. Octapharma AG
  • 11. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GUILLAIN-BARRE SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GUILLAIN-BARRE SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GUILLAIN-BARRE SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR & SENSORY AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MILLER FISHER SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023